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Comparing the effectiveness profile of pharmacological interventions used for 
orthodontic pain relief – An arm-based multilevel network meta-analysis of longitudinal 
data   
Summary  
Background and Objectives: To compare the effectiveness profile of various analgesics used 
for orthodontic pain relief over a one week time period by conducting a longitudinal network 
meta-analysis (NMA)  
Search methods: The MEDLINE, EMBASE, and the Cochrane Central Register of Controlled 
Trials databases were searched till 31st December 2015 to identify the relevant studies. 
Additional studies were identified by hand searching journals and reference lists. Unpublished 
literature was also searched.  
Selection criteria: Eligible studies were randomised-controlled trials (RCTs) evaluating the 
effectiveness of pharmacological interventions for pain relief after placement of separator or 
initial aligning arch wire. 
Data collection and analysis: Pain intensity data at 2 hours, 6 hours, 12 hours, 24 hours, 36 
hours, 48 hours, 72 hours, 96 hours, and 168 hours was collected. In addition, data was also 
extracted for potential covariates (age, sex and procedure). A covariate-adjusted arm-based 
multilevel random coefficient model was used for evidence synthesis.  
Results: 15 RCTs (1,341 participants; male/females 595, 44.6% / 746 55.4%; mean age 17.3 
years, SD 4.1) were included. A total of 11 Nodes (Acetaminophen, Aspirin, Etoricoxib, 
Flurbiprofen, Ibuprofen, Lumiracoxib, Meloxicam, Naproxen, Piroxicam, Placebo and 
Control) were identified out of which 5 Nodes (Placebo, Ibuprofen, Naproxen, Acetaminophen 
and Aspirin) had Subnodes (based on timing of administration). Compared to Control, Placebo, 
Flurbiprofen, Lumiracoxib and Meloxicam were not significantly effective. Etoricoxib (most 
effective) and Piroxicam (second most effective) were effective over a long period which lasted 
up to 96 hours and 72 hours, respectively. Ibuprofen, Acetaminophen, Naproxen and Aspirin 
were effective at 6 hours, 12 hours, and 24 hours. The effectiveness of these analgesics was 
significantly influenced by the timing of administration. Assessment of heterogeneity, 
transitivity, inconsistency, and publication bias revealed no major threat to the NMA derived 
estimates.  
Conclusion: Compared to the Control, Placebo was least effective whereas Etoricoxib was 
most effective analgesic in reducing orthodontic pain. Administration timing has significant 
influence on the effectiveness profile of analgesics routinely used for managing orthodontic 
pain.  
Registration: Not registered 
Conflict of interest: None 
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Introduction 
Various methods have been proposed to manage orthodontic pain which include 
pharmacological and non-pharmacological interventions. However, pharmacological 
interventions are more effective, and therefore, are most commonly used for orthodontic pain 
management (1). Recently, pairwise meta-analyses (PMAs) were conducted to evaluate the 
relative effectiveness of pharmacological interventions used for orthodontic pain relief after 
separators and/or initial arch wire placement (1, 2).  
However, PMAs are limited in their Comparative Effectiveness Research (CER) based 
decision making value because such conventional meta-analysis approach does not utilize all 
the available evidence if direct comparisons are not provided by all studies included in the 
analysis (3, 4). Network meta-analysis (NMA) has extended this concept of CER by providing 
estimates for comparative effectiveness of all competing interventions even when no head-head 
comparisons are available (3, 4). Recently, Sandhu et al (5) conducted a NMA to examine the 
effectiveness of  various intentions used for orthodontic pain relief. However, authors restricted 
their NMA to synthesize evidence for comparative effectiveness of various competing 
interventions for a single time point. 
Recent advancements in NMA methodology within a framework of multilevel 
modelling allow appropriate handling of more complex data (such as correlated longitudinal 
data) in evidence synthesis; and to take into account the variability in treatment definitions (e.g. 
based on timing of administration) across network (6-9). Further, an arm-based NMA approach 
does not require a common comparator across the network (4).  
In this review, an arm-based covariate adjusted multilevel NMA of repeated measure 
data was undertaken to address the specific research question which was defined within the 
PICOS (Population, Interventions, Comparator, Outcome, and Study type) framework. 
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Objective was to synthesize evidence based on the randomized clinical trials (RCTs) to 
compare the effectiveness profile of various competing pharmacological interventions against 
control for pain relief over a one week time for male and female participants undergoing 
orthodontic treatment after placement of orthodontic separator or initial arch wire. The 
selection of aforementioned time frame, i.e. one week, was based on the fact that it represents 
the clinically meaningful time period in terms of change in pain intensity level (10-12). We 
decided to include studies with orthodontic separator or initial arch wire because the patterns 
and magnitude of pain after placement of separator and initial arch are similar (10-13). 
Methods  
We followed a standard systematic review protocol according to the PRISMA 
(Preferred Reporting Items for Systematic reviews and Meta-Analysis) guidelines (14). 
However, this systematic review was not registered as a priori. Eligibility criteria and search 
strategy were designed to ensure that all possible pharmacological interventions used for 
orthodontic pain management are included in this NMA.  
Eligibility criteria  
Eligible studies were prospective randomised-controlled trials (RCTs) evaluating the 
effectiveness of pharmacological interventions over a one week time. To safeguard against 
violation of transitivity and consistency assumptions in NMA, we included studies with 
comparable design characteristics (objectives, methodology and outcome) and plausible range 
of covariate (e.g. age and sex) distribution (15). The target population was defined as the 
children and adults (both males and females) who required placement of orthodontic separator 
or initial arch wire as a part of their fixed orthodontic treatment.  
Considering the fact that administration timing of pharmacological interventions varies 
(i.e. pre-operative, post-operative, and combination of pre-operative and post-operative) from 
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study to study, we decided to take into account this variability in treatment definition, as 
recommended (9). Please refer to Section A of Appendix 1 (Online Supplementary Material) 
for details.  
The index for comparative effectiveness (outcome) amongst interventions was the 
difference in patient reported pain intensity level after separator or initial arch wire placement. 
Since we conducted an arm-based NMA, there was no need for studies to have a common 
comparator in all studies. This because in an arm-based NMA, it is assumed that each study 
hypothetically compares all interventions, many of which are missing by design and thus can 
be considered as missing at random (4).  However, to compare an intervention effect against a 
single reference group, we used the ‘Control’ group as a comparator in our presentation of 
results of the NMA.  
Search strategy  
The MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL, The 
Cochrane Library), and EMBASE databases were searched to identify the randomized clinical 
trials (RCTs). These databases were searched till December 31, 2015 without any restriction 
for starting date of search, publication language or publication status (ahead of publication as 
online; or as print in the Journal). To eliminate the possibility of excluding any intervention 
from its inclusion in this NMA, we did not use interventions as search item, rather we searched 
all studies which had the keyword pain or discomfort in the title and/or abstract. All such 
retrieved studies were then searched to find whether these studies used any pharmacological 
intervention for orthodontic pain relief.  
Additional studies were identified by hand searching of all volumes and issues of 
following four major orthodontic journals from 1980 to December, 2015: American Journal of 
Orthodontics and Dentofacial Orthopaedics, The Angle Orthodontist, the European Journal of 
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Orthodontics and the Journal of Orthodontics. Reference lists of the included studies and 
previously published systematic reviews/meta-analysis related to the topic were screened for 
identification of any additional study. Unpublished literature was searched in Pro-Quest 
Dissertations & Theses database, ClinicalTrials.gov, and National Research Register using 
“orthodontic” and “pain” as search terms. Conference proceedings and abstracts were also 
accessed where possible.  
Study selection and data extraction  
The titles and abstracts of all studies identified by the search strategies were 
independently screened by the first author (S.S.S) for removal of duplicate entries and studies 
which failed to meet the objectives of this NMA. Full-text articles of remaining studies were 
assessed independently by two authors (S.S.S and H.S.K) for eligibility based on the predefined 
criteria. When disagreement occurred, the article was re-read and discussed until a consensus 
was obtained amongst the authors. A record of all decisions made about the identified studies 
was kept. The review authors were not blinded to author(s), institution or site of publication of 
studies.  
Study characteristics data was extracted independently by two review authors (S.S.S 
and H.S.K) using a pilot tested data extraction form. We resolved disagreement by mutual 
discussion and, if required, by consultation with a third author. The data extracted was: 1) study 
identification: first author’s name and year of publication, 2) study design, 3) population 
(participants): sample size, mean age, number of male and female participants, and female 
proportion, 4) interventions: details of pharmacological interventions including the dose, 
frequency, mode and timing of administration, 5) comparator, and 6) outcome assessment. 
Details of data extracted, and the methodology used to extract the required data is 
presented in the Section B of Appendix 1 (Online Supplementary Material). Briefly, the 
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predefined primary outcome of interest was the patient reported pain intensity level over a one 
week time. We included trials which assessed pain intensity by using a 100 mm Visual 
Analogue Scale (VAS) or a 10 cm VAS scale. We extracted data for each time point as reported 
in each individual study. The earliest time point for outcome assessment reported across studies 
was 0 hours (baseline), i.e., before randomization. The farthest time point for outcome 
assessment was 168 hours (day 7) after separator or initial arch wire placement. The total 
number of time points identified across all studies for outcome assessment was 10; time points 
were defined as 0 hours (baseline), 2 hours, 6 hours, 12 hours, 24 hours (day 1), 36 hours (day 
1 night), 48 hours (day 2), 72 hours (day 3), 96 hours (day 4), and 168 hours (day 7). If a trial 
reported multiple effect sizes (e.g. at rest, during fitting teeth together etc.), we combined these 
effect sizes to get a single estimate, as recommended (14). We followed a recommended 
procedure to extract relevant data from non-parallel (split-mouth and cross-over) design RCT 
in order to include it in the meta-analysis along with the rest of the parallel design RCTs (14). 
Based on the evidence available on the potential confounders influencing the outcome in pain 
trials, we extracted data for five potential confounders which were to be included as a priori 
covariates in our NMA. Out of these five potential covariates, three were patient level (age, sex 
and baseline pain) covariates (16-18), and two were study level covariates (the double blinding 
procedure (19) and the orthodontic procedure (10, 11)).   
Risk of bias assessment for studies included trials 
Risk of bias was assessed independently by two authors (S.S.S and H.S.K) and all 
disagreements were resolved by discussions. The Cochrane Collaboration risk-of-bias tool (14) 
was used to assess the risk of bias based on the following domains: random sequence 
generation, allocation concealment, blinding of participants and personnel, blinding of 
assessors, incomplete outcome data, selective reporting of outcomes and ‘others’ sources of 
bias. The ‘others’ source of bias was based on the assessment whether male and female 
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participants were similar with respect to the mean age. This ‘others’ source of bias was used to 
assess the transitivity assumption. Risk of bias assessment was based on the reported 
information and no attempt was made to contact the authors for clarification. If information 
was not sufficient to ascertain the level of bias (High vs Low), we assigned the level ‘Unclear’ 
for risk of bias. 
Statistical analysis  
Data was analysed with SAS 9.4 software (SAS Institute Inc., Cary, NC, USA).  Mixed 
model analysis (PROC GLIMMIX) was employed to analyse repeated measures data (VAS 
score) appropriately accounting for the correlated nature of the data (20) and assuming 
normality of the response. The statistical significance level was set at 0.05. The effect size 
(mean difference) was considered significant if a 95% Confidence Interval (CI) did not include 
‘zero’. The Stata software (21) version 14 (StataCorp, College Station, Tex) was used for 
ranking interventions based on a multidimensional scaling (MDS) approach (22). The required 
pairwise estimates were derived from the mixed model analysis (PROC GLIMMIX). For 
plotting the network evidence, we used the ‘igraph’ package (version 1.0.1) in R (version 3.2.4) 
software. Time was modelled as continuous variable. The unit of time in this NMA was hour, 
ranging from 2 hours to 168 hours (day 7). It was decided that baseline pain, i.e., pain 
assessment before randomization (time ‘0’ hours), would be used as a covariate.  
Details of methodological background, the analytical strategies including modelling of 
the time variable, description of various models explored for current NMA, and model fitting 
and its evaluation are described in the Section A, Section B and Section C of Appendix 1 
respectively (Online Supplementary Material). Briefly, a recently developed arm-based 
multilevel (mixed effect) modelling approach within a framework of two-way factorial 
analysis-of-variance (ANOVA) was used (7). The data constituted a hierarchical structure with 
repeated measure outcome nested in Subnodes which in turn were nested in Nodes. An inverse 
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variance weighed quadratic random coefficient model was fitted using the restricted maximum 
likelihood (method=RMPL) method of estimation and Kenward-Roger degree of freedom (20).  
Age, sex (proportion of females) and procedure (separator or initial arch wire) were 
entered into the model as a part of network meta-regression (15). These covariates were 
included to adjust the parameters estimates for the potential confounding effect on the outcome 
(i.e. pain). The reasons for excluding other covariates are provided in the Appendix 1 (Online 
Supplementary Material). 
Testing assumptions of transitivity, consistency, heterogeneity and publication bias  
Details are provided in the Section D of Appendix I (Online Supplementary Material). 
The plausibility of transitivity assumption was evaluated based on the design characteristics 
and the methodology of studies included in the NMA, as recommended (23). We adopted and 
extended the design-by-treatment interaction approach recently used by Piepho et al (6) for 
evaluation of heterogeneity and inconsistency across a network in arm-based NMA. To assess 
publication bias, i.e., small study effects (effect size with large standard error, SE), we adopted 
a similar approach as was used in a recent NMA (8). In this approach, a study-level explanatory 
variable representing a measure of precision (Standard Error) was added to test if the 
intervention effect varies with the study precision.  
Although it is a routine practice to conduct a conventional pairwise meta-analysis 
(PMA) as part of evidence synthesis in order to assess the agreement/disagreement between 
the direct estimates derived from the PMA and NMA, (23) we realized that it was not feasible 
and informative in this current review. This was because of the complexity of model and limited 
data available to derive a meaningful interpretation of PMA findings. Please refer to Section E 
of Appendix 1 (Online Supplementary Material) for more details. 
Results  
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Search results and characteristics of studies included in the NMA 
The search strategy details are provided in the Appendix 2 (Online Supplementary 
Material). A total of 256 RCTs were identified by the search strategy. After removing duplicate 
records (108) and studies such systematic reviews and trials which either did not use 
orthodontic separator/initial arch wire as part of orthodontic procedure or did not assess pain 
as outcome etc. (101), we were left with a total of 47 RCTs for which full text articles were 
obtained to select relevant RCTs to be included in this review. After scrutinizing the full text 
articles, for the predefined eligibility criteria, in total 15 RCTs (24-38) were included in this 
review. The PRISMA flow diagram is shown as Figure 1. Further details are provided in the 
Section F of Appendix 1 (Online Supplementary Material). 
The characteristics of studies included in the NMA are presented in the Appendix 3 
(Online Supplementary Material) and summarised in Table 1. Total 1,341 participants (595 
male, 44.6%; females=746, 55.4%) were included with mean age of 17.3 years (SD 4.1), and 
mean baseline pain VAS score 2.54 (SD 0.6). Eleven RCTs (73.3 %) used orthodontic separator 
as orthodontic procedure (24-27, 29-32, 36-38) whereas the remaining 4 RCTs (26.7 %) used 
initial arch wire as orthodontic procedure (28, 33-35). Except one RCT (26), all trials were 
single centre trials.  
Two RCTs were two-arm trial (25, 26), 10 RCTs were three-arm trials (24, 27-31, 33, 
35, 36, 38), two RCTs were four-arm trials (32, 37) and one RCT was a six-arm trial (34). 
Except one RCT (32), which was a cross-over trial, all remaining 14 RCTs were from parallel 
arm designs. Since there was no evidence of carry-over effects, the cross-over design RCT, 
which compared four interventions, qualified for inclusion as a four-arm trial in the NMA along 
with other parallel design trials (as explained in the methodology section).  
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VAS was used for outcome (pain) assessment across all studies. The time of outcome 
assessment varied from 2 hrs to 168 hrs (day 7). Two RCTs (13.3 %) recorded baseline 
assessment of pain before randomization and analgesics administration (25, 35). The number 
of studies contributing to data at each time point was as follows (with number of studies in 
parentheses): baseline (2), 2 hours (15), 6 hours (15), 12 hours (11), 24 hours (15), 36 hours 
(2), 48 hours (12), 72 hours (9), 96 hours (3), and 168 hours (9). 
Description of Network  
The evidence network plots are shown in Figure 2. In all, 11 Nodes (Acetaminophen, 
Aspirin, Etoricoxib, Flurbiprofen, Ibuprofen, Lumiracoxib, Meloxicam, Naproxen, Piroxicam, 
Placebo and Control) were identified, out of which 5 Nodes (Placebo, Ibuprofen, Naproxen, 
Acetaminophen and Aspirin) had Subnodes (based on timing of administration). Placebo, 
Ibuprofen and Acetaminophen had three Subnodes whereas Naproxen and Aspirin had two 
Subnodes. The details are provided in Table 1.  
Risk of bias assessment 
Risk of bias assessed for each individual study is shown in Figure 3. There was no 
evidence for high risk of bias for randomization and allocation procedures, though few studies 
did not provide relevant information and thus were assigned the level ‘unclear risk of bias’. 
Since we were investigating the efficacy of pharmacological interventions, the focus for 
evaluation of risk of bias related to the blinding was based on the ‘double blinding’ procedure. 
Therefore, based on the consensus amongst authors, a high risk of bias was assigned to a study 
if it failed to meet the criteria for double blinding. We identified one study (30) with high risk 
of bias for blinding. 
Model fit evolution and testing assumptions of transitivity, consistency, heterogeneity and 
publication bias 
11 
 
The best fitting model identified was one with random intercept and slope (random 
coefficients) at study level as well as at the level of nested random structure 
(Study/Node/Subnode). All models described are covariate adjusted unless otherwise stated. 
Please see Section C of Appendix 1 (Online Supplementary Material) for more details. Results 
for multilevel model assumption evaluation (e.g. normality, autocorrelation of residuals etc.) 
and model fit assessment are shown in Appendices 4 and 5 (Online Supplementary Material). 
A careful evaluation of methodology and other characteristics of studies (Appendix 3 
of Online Supplementary Material) included in this NMA revealed no potential threat to the 
transitivity assumption. Results for joint global test for inconsistency and heterogeneity showed 
no evidence of significant inconsistency or heterogeneity at Node or Subnode level. Due to the 
sparsity of data in terms of number of studies per design, as shown in Table S1 of Appendix 1 
(Online Supplementary Material), we could not investigate the design specific-contribution to 
overall heterogeneity (study-by-design-by-intervention interaction) across the network. 
Findings of meta-regression based approach used to assess publication bias (small study 
effect) revealed no significant publication bias at Node level. However, there was an evidence 
for significant publication bias for Subnodes corresponding to two Nodes, namely, Ibuprofen 
and Placebo. Compared to Pre-operative Ibuprofen, the small study effect significantly 
enhanced the (apparent) effectiveness (i.e. slow rise in pain) of Ibuprofen administered as 
combined Pre-operative and Post-operative analgesia and also resulted in significantly faster 
deceleration in the rise in pain. On the contrary, compared to Pre-operative Placebo, the small 
study effect significantly decreased the effectiveness of Placebo administered as combined Pre- 
operative and Post-operative analgesia as well as resulted in significantly slower deceleration 
in the rise of pain. Readers are referred to Section G of Appendix 1 (Online Supplementary 
Material) for more details about findings of transitivity, consistency, heterogeneity and 
publication bias assessment. 
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Network meta-analysis results 
Results for covariate adjusted and non-adjusted quadratic random effect network meta-
analysis are shown in Table S3 and Table S4, respectively of Appendix 1 (Online 
Supplementary Material). Since model fit was substantially better for the covariate adjusted 
model, we will be presenting results derived from the covariate adjusted network meta-
analysis. Detailed interpretation of regression estimates derived from the covariate adjusted 
NMA (Table S3) model are provided in the Section H of Appendix 1 (Online Supplementary 
Material). 
Our model allows estimation of interventions’ effectiveness (Node) as well as the effect 
of administration timing (Subnode) on the effectiveness profile and since it is more meaningful 
to have a clear understanding of effectiveness profile at each time point compared to the 
Control group, we will be presenting these results in the following sections. Reader are referred 
to Section H of Appendix 1 (Online Supplementary Material) for more detailed description of 
findings. 
Node Effectives at each time point (compared to Control group)  
The forest plots showing the comparative effectiveness (estimate as well as the 
corresponding 95% Confidence Intervals) of each Node are displayed as Figure 4 through 
Figure 12. An estimate was considered significant if the corresponding 95% CI did not include 
zero. It is worth noting that estimates are more precise for Nodes (Placebo, Ibuprofen, 
Naproxen, Acetaminophen and Aspirin) which have nested Subnodes. More detailed results 
(regression curves and profile plots) are provided in the Appendix 6 (Online Supplementary 
Material). 
Etoricoxib was most effective intervention throughout a one week time period with its 
effectiveness reaching a peak at around 12 to 24 hours. Except for 168 hours (day 7), Etoricoxib 
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was significantly effective in reducing pain when compared to the Control group. Piroxicam 
was significantly effective at 2 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours; 
whereas Naproxen was significantly effective at 2 hours, 6 hours, 12 hours, 24 hours, and 36 
hours. The effectiveness profile of Ibuprofen, Aspirin and Acetaminophen was similar as these 
three interventions were effective at 6 hours, 12 hours and 24 hours. Placebo, Flurbiprofen, 
Lumiracoxib and Meloxicam were not significantly effective compared to the Control group at 
any of the time points included in this longitudinal NMA. 
The pairwise differences for Nodes are provided in the Appendix 7 of Online 
Supplementary Material. The ranking of Nodes (compared to Control group) derived from 
these pairwise differences based on the Unique Dimension approach is provided in Table 2 and 
displayed as graph in Appendix 8 of Online Supplementary Material. Over the entire one week 
time period, Etoricoxib was most effective intervention (rank 1) whereas Placebo (rank 10) 
was the least effective intervention. 
Subnode Effectives at each time point (compared to Control group)  
Except for Placebo, the differences in the administration timing of all other four Nodes 
(with Subnodes) had significant influence on the effectiveness profile over time. The regression 
curves, forest plots as well as the profile plots are shown in the Appendix 9 of the Online 
Supplementary Material.   
Acetaminophen, Aspirin, Ibuprofen and Naproxen administered as combination of pre- 
operative and post-operative analgesia were more effective as compared to administration of 
either pre-operative or post-operative analgesia. Pre-operative Acetaminophen was 
significantly effective only at 6 hours whereas the combination of pre-operative and 
postoperative Acetaminophen was significantly effective at 6 hours, 12 hours, 24 hours, 36 
hours, and 48 hours. Aspirin administered as post-operative was not effective at any of the time 
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points but when administered as combined pre-operative and post-operative analgesia, it was 
significantly effective at 2 hours, 6 hours, 12 hours, 24 hours, 36 hours, 48 hours, and 72 hours. 
Administration of Ibuprofen as combination of pre-operative and post-operative analgesia was 
significantly effective at 2 hours, 6 hours, 12 hours, 24 hours, 36 hours, and 48 hours whereas 
when administered as either pre-operative or post-operative, it was not significantly effective. 
Naproxen administered as pre-operative analgesia was significantly effective only at 2 hours 
whereas its administration as combined pre-operative and post-operative analgesia was 
significantly effective at 6 hours, 12 hours, 24 hours, 36, and 48 hours.  
The pairwise differences for Subnodes are provided in Appendix 10 of Online 
Supplementary Material. The ranking of Subnodes estimated from the pairwise differences 
based on the Unique Dimension approach is provided in Table 3 and displayed as graph in 
Appendix 11 of Online Supplementary Material.  
Considering the large number of possible pairwise comparisons for Nodes and 
Subnodes across nine different time point in this NMA, we did not undertake the Grading of 
Recommendations Assessment, Development (GRADE) assessment. One option was to 
perform GRADE assessment for overall estimates but this did not seem appropriate because 
our findings and interpretations were based on the interventions’ effectiveness at individual 
time points.  
Discussion 
In general, our results substantiate various claims made recently in relation to the NMA. 
First, multilevel analysis of hierarchical data structure does provide precise estimates even 
when number of interventions is large and few studies are available for each comparison (5, 8, 
9). This gain in precision was more pronounced for Nodes which had at least two Subnodes. 
Second, categorizing interventions (Subnodes) into their respective Nodes based on their 
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timing of administration did provide a valuable insight into the relative effectiveness of each 
intervention as a function of administration timing. This finding is in complete concurrence 
with the evidence provided by Giovane et al. (9) who concluded that network meta-analysis 
models should appropriately account for the variability in the intervention definitions in order 
to draw a meaningful interpretation of relative effectiveness.  
Results show that compared to the Control group, Placebo, Flurbiprofen, Lumiracoxib 
and Meloxicam were not significantly effective in reducing pain at any of the time points 
included in this longitudinal NMA. Placebo was least effective and this finding is in agreement 
with the results of a recent meta-analysis (39) as well as a network meta-analysis (5) wherein 
the authors concluded that placebo response is significant only at the earliest time period within 
few minutes (39) and there is no evidence of significant placebo response at longer time periods 
(5, 39).  
Etoricoxib, administered as combined pre-operative and post-operative analgesia, was 
the most effective intervention. This finding is in agreement with previous studies which 
reported that etoricoxib is more effective in reducing the acute pain, including orthodontic pain 
(5) as compared to other commonly used NSAIDs (40). Etoricoxib is a second-generation, 
highly selective cyclooxygenase 2 (COX-2) inhibitor with anti-inflammatory and analgesic 
properties (41). It has a dose-dependent inhibitory effect on COX-2 across the therapeutic dose 
range and possesses a long plasma half-life duration of 22 h (41). The high effectiveness of 
Etoricoxib observed in our NMA could be attributed to the fact that due to its administration 
as combined pre-operative and post-operative analgesia, there was an accumulative dose of 
120 mg (60 mg pre-operative and 60 mg post-operative) administered within few hours (as 
evident from the study characteristics shown in Appendix 3 of Online Supplementary 
Material), thereby enhancing its effectiveness which is a dose-dependent phenomenon. 
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Our findings provided interesting insights into the pharmacokinetics-driven 
effectiveness of various analgesics used for managing orthodontic pain. Results show that the 
effectiveness of analgesics depends on the pharmacokinetics, and, therefore, should be 
carefully considered during the selection of analgesics in terms of administration timings. For 
example, analgesics with long plasma half-life, like Pirocixam (18-20 h), Naproxen 
(approximately 15 h) and Lumiracoxib (12 h) were effective over the longer time period even 
when administered as only pre-operative analgesic (41). On the contrary, the analgesics with 
shorter plasm half-life like Ibuprofen (4-8 h), Acetaminophen (2-5 h) and Aspirin 
(approximately 6 h) were effective over a longer time period only if these analgesics were 
administered as combination of pre-operative and post-operative analgesics (41). 
We are aware of only one NMA reported in the orthodontic literature which provided 
the comparative effectiveness of interventions used for orthodontic pain relief (5). However, 
unlike our NMA which was based on a longitudinal data, previous NMA (5) included only a 
single time point (24 hours) for evidence synthesis. Therefore, we believe that the current NMA 
is an important advancement in the direction to evaluate the effectiveness profile of analgesics, 
particularly in assessing the effect of administration timing on the effectiveness over a one 
week time period. In general, our findings support the evidence provided by other authors (5) 
that placebo is least effective whereas Etoricoxib is most effective in managing orthodontic 
pain over a one week time period, including a peak pain intensity level at 24 hours.  
Implications for practice and research 
Findings of this NMA suggest that prescription of pharmacological interventions 
(analgesics) should be guided by an appropriate knowledge of their mechanism of action as 
well as the pharmacokinetics such as plasma half-life period. Based on such knowledge, a 
clinician may build his/her own analgesic protocol using the multimodal analgesia. An 
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important component of multimodal analgesic therapy is the pre-operative analgesia followed 
by adjuncts analgesics in form of post-operative analgesics. Pre-operative analgesia is an 
anticipatory anaesthetic approach that intends to prevent the pain and inflammatory response 
initiated by surgical incision and manipulation, and prevent the "wind-up phenomenon'' (41). 
We also believe that our NMA would help in guiding the design of future trials in orthodontic 
pain management. This would fill the existing gap wherein no evidence is available for the 
possible effect of administration timing on the effectiveness profile of few analgesics used for 
managing orthodontic pain.  
However, we would like to highlight the fact that since we synthesized evidence for the 
comparative effectiveness based on only therapeutic efficacy, and not on combined therapeutic 
efficacy and adverse effects (because studies did not report adverse effects), the above 
statements are generalized in nature and not specific.  
Strengths and limitations 
The strengths of this NMA include: a) we were able to extract the required data from 
all 15 relevant RCTs identified by a comprehensive search strategy, thus minimizing the 
selection and reporting bias; b) the novel multilevel analysis approach used to perform NMA 
imparts confidence in our results because such an approach can handle a complex network of 
evidence with sparse data (even does not require a common controls to be present in all trials), 
and yet provide precise estimates owing to the borrowing of strength across; c) lastly, the 
current model allowed us to have independent estimates and rankings of each individual Node 
as well as Subnode. 
However, there are many limitations: a) Perhaps the most important limitation relates 
to the fact that few interventions (Nodes) included in this NMA did not provide data for the 
corresponding Subnode because of their single administration timing (pre-operative or post-
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operative analgesia only). Thus, the precision of estimates varied across Nodes and few 
estimates had wide confidence intervals. However, the analytical methodology adopted in this 
NMA minimized such variability; b) there was an evidence for significant publication bias at 
Subnode level. However, this bias was confined to only two Subnodes (Ibuprofen and Placebo), 
and therefore we believe that it did not substantially affect the NMA estimates across the 
network; c) due to the limited number of studies available in each design, we were unable to 
quantify and locate the design specific heterogeneity and inconsistency across network. 
However, a joint global test for heterogeneity and inconsistency showed that there was no 
significant threat to the NMA estimates; and d) lastly, because of limited number of studies 
and relatively large number of interventions included in this NMA, we were unable to conduct 
few sensitivity analysis such as: i) to evaluate effect of  network geometry on the NMA, ii) to 
examine impact of Nodes associated with publication bias on estimates by eliminating these 
Nodes from the network, and iii) to see if risk of bias had any influence on the estimate and 
ranking of intervention. An attempt to undertake first two sensitivity analysis could have 
resulted in an unconnected network structure, therefore was not feasible; whereas third 
sensitivity analysis deemed inappropriate, as explained next. An appropriate strategy to 
examine the effect of risk of bias for any domain, say for example double blinding, was to 
include a dummy covariate (e.g. 0, low risk; 1, high risk) within the framework of network 
meta-regression. However, since only one study had high risk of bias for double blinding (and 
rest all with low risk of bias), the results could have been misleading due to the ecological bias, 
a phenomenon well known for meta-regression. Similar implications were for other domains 
of risk of bias.  
Conclusions  
Results show that placebo response is not effective in managing orthodontic pain at any 
time point after orthodontic separator or initial arch wire placement. Etoricoxib seems to be 
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most effective analgesic over the entire one week duration after administration owing to its 
dose-dependent analgesic effectiveness and long plasma half-life period. Timing of 
administration has significant influence on the effectiveness profile of analgesics due to the 
inherent variability in the plasma half-life of various analgesics used for orthodontic pain 
management.   
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Figure captions  
Figure 1 PRISMA flow diagram. 
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Figure 2 Network evidence plots at Node and Subnode level. Thickness of Nodes/Subnodes 
correspond to the total number of studies. The edge thickness (with numbers) shows the total 
number of studies making a direct comparison. 
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Figure 3 Risk of bias summary. 
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Figure 4 Forest plot showing Nodes effectiveness at 2 hours (compared to control group). 
 
 
Figure 5 Forest plot showing Nodes effectiveness at 6 hours (compared to control group). 
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Figure 6 Forest plot showing Nodes effectiveness at 12 hours (compared to control group). 
 
 
Figure 7 Forest plot showing Nodes effectiveness at 24 hours (compared to control group). 
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Figure 8 Forest plot showing Nodes effectiveness at 36 hours (compared to control group). 
 
 
Figure 9 Forest plot showing Nodes effectiveness at 48 hours (compared to control group). 
 
  
26 
 
Figure 10 Forest plot showing Nodes effectiveness at 72 hours (compared to control group). 
 
 
Figure 11 Forest plot showing Nodes effectiveness at 96 hours (compared to control group). 
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Figure 12 Forest plot showing Nodes effectiveness at 168 hours (compared to control group). 
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